Related Experiment Video
Updated: Mar 9, 2026
08:00
Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
Published on: October 11, 2019
8.0K
Prognostic impact of LAT1 and CD98 expression in cutaneous angiosarcoma
Neoplasma
|January 6, 2017
Summary
Low expression of CD98, a transporter protein, predicts poor prognosis in cutaneous angiosarcoma patients. This finding offers a novel biomarker for this aggressive cancer, impacting survival predictions.
Area of Science:
- Oncology
- Cancer Biology
- Biomarker Discovery
Background:
- L-type amino acid transporter 1 (LAT1) and CD98 are implicated in cancer aggressiveness and survival.
- Expression patterns of LAT1 and CD98 in cutaneous angiosarcoma remain largely uncharacterized.
Purpose of the Study:
- To investigate the clinicopathological significance of LAT1 and CD98 expression in cutaneous angiosarcoma.
- To identify potential prognostic biomarkers for this rare cancer.
Main Methods:
- Retrospective review of 52 cutaneous angiosarcoma cases.
- Immunohistochemical staining for LAT1, CD98, and Ki-67.
- Statistical analysis including multivariate analysis for prognostic prediction.
Main Results:
- High expression rates for LAT1 (56%) and CD98 (79%) were observed.
- CD98 expression was significantly higher than LAT1 expression (p=0.021).
- Low CD98 expression correlated significantly with distant metastasis (p=0.044) and predicted poor prognosis.
Conclusions:
- Low CD98 expression is a novel and significant prognostic biomarker in cutaneous angiosarcoma.
- LAT1 expression did not show a significant correlation with patient prognosis.
